April 25, 2024
14 min listen
Save

Healio Minute Podcast, Rheumatology/Psoriatic Arthritis Edition: Top Headlines - Week of April 22, 2024

In this edition, FDA approves Selarsdi as Stelara biosimilar, deucravacitinib improves ‘broad range’ of patient-reported outcomes and more.

Read the full coverage here:

FDA approves Selarsdi as Stelara biosimilar for psoriasis, psoriatic arthritis

Deucravacitinib improves ‘broad range’ of patient-reported psoriatic arthritis outcomes

Advanced therapy not enough for nearly 75% of Canadian patients with psoriatic arthritis

New EULAR recommendations for psoriatic arthritis urge biologics after methotrexate failure

Dactylitis, enthesitis resolution linked to less pain, fatigue in guselkumab-treated PsA

References:

Gladman DD, et al. J Rheumatol. 2024;doi:10.3899/jrheum.2023-0716.

Gossec L, et al. Ann Rheum Dis. 2024;doi:10.1136/ard-2024-225531.

Press Release

Rahman P, et al. Clin Rheumatol. 2024;doi:10.1007/s10067-024-06921-8.

Strand V, et al. Arthritis Care Res. 2024;doi:10.1002/acr.25333.

Sources/Disclosures

Collapse

Disclosures: Please see each study for relevant financial disclosures.